

Malignant mesothelioma - can we improve quality of life?

Submission date 12/12/2013	Recruitment status No longer recruiting	☒ Prospectively registered ☒ Protocol
Registration date 31/01/2014	Overall study status Completed	☐ Statistical analysis plan ☒ Results
Last Edited 25/03/2020	Condition category Cancer	☐ Individual participant data

Plain English summary of protocol

<https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-study-looking-improving-quality-life-people-mesothelioma-chest-respect-meso>

Contact information

Type(s)

Scientific

Contact name

Prof Anoop Chauhan

Contact details

Portsmouth Hospitals NHS Trust
Department of Respiratory Medicine
Queen Alexandra Hospital
Southwick Hill road
Cosham
Portsmouth
United Kingdom
PO6 3LY
+44 (0)23 9228 6000
chief-investigator-ajc@respect-meso.org

Additional identifiers

ClinicalTrials.gov (NCT)

NCT03068117

Protocol serial number

RESPECT-Meso 6.0, 17/02/2015

Study information

Scientific Title

A multicentre non-blinded randomised controlled trial to assess the impact of Regular Early SPEcialist symptom Control Treatment on quality of life in malignant Mesothelioma - 'RESPECT-Meso'

Acronym

RESPECT-Meso

Study objectives

Can early referral to specialist palliative care services in newly diagnosed mesothelioma patients result in improved quality of life for patients and their caregivers?

Ethics approval required

Old ethics approval format

Ethics approval(s)

NRES Committee London - Hampstead , 26/01/2012, ref: 12/LO/0078

Primary study design

Interventional

Study design

Multi-centre randomised non-blinded parallel group controlled trial

Study type(s)

Quality of life

Health condition(s) or problem(s) studied

Mesothelioma

Interventions

Regular early Specialist Symptom Control Treatment (SSCT) and Standard Therapy.

In the regular early SSCT group, patients will be seen within three weeks of randomisation by the SPC team (regardless of, and in addition to, all other treatments being offered). The initial meeting will be an approximately 1 hour consultation with a member of the Specialist Palliative Care team. This may be either a Consultant or Specialist Palliative Care Clinical Nurse Specialist (SPCCNS).

Patients will then continue to be seen regularly on at least a 4 weekly basis (regardless of other treatments, interventions and symptoms) by a member of the SPCT, with consultations lasting approximately 30 minutes. These monthly reviews will continue until end of trial (EOT) or patient death.

Intervention Type

Other

Phase

Not Applicable

Primary outcome(s)

The primary objective of this randomised controlled study is to assess the impact of regular early specialist symptom control treatment (SSCT) involvement on global quality of life (QOL) in patients recently diagnosed with malignant pleural mesothelioma (MPM) 12 weeks post randomisation as compared to standard care.

Key secondary outcome(s)

The secondary objectives are to assess the impact of regular early SSCT involvement in the care of patients recently diagnosed with MPM on the following:

1. QOL in patients after 24 weeks
2. Patient mood at 12 and 24 weeks
3. Primary caregiver QOL and mood at 12 and 24 weeks, and 24 weeks after patient death
4. Overall survival between the two study groups
5. Healthcare utilisation and healthcare costs
6. The cost-effectiveness of regular early SSCT when compared to usual practice

Added 21/08/2014:

7. Sub-group analysis of HRQoL at 12 and 24 weeks for patients based on the neutrophil, lymphocyte ratio and radiological staging at time of diagnosis

Completion date

31/03/2017

Eligibility

Key inclusion criteria

1. Histological or cytological confirmation of malignant pleural mesothelioma (MPM)
2. Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0-1. (Asymptomatic patients score 0; symptomatic but ambulatory patients score 1)
3. The diagnosis of MPM received within the last 6 weeks
4. Ability to provide written informed consent in English and comply with trial procedures
5. Males and females aged 18 and over

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 Years

Sex

All

Total final enrolment

174

Key exclusion criteria

Current exclusion criteria as of 21/09/2015:

1. Other known malignancy within 5 years (excluding localised squamous cell carcinoma of the skin, cervical intraepithelial neoplasia, grade III and low grade prostate cancer (Gleason score <5, with no metastases)).
2. Significant morbidity which the lead physician (or MDT) feel will unduly confound or influence QOL.
3. Those patients the MDT judge require referral to the SPCT at the point of diagnosis.
4. Concurrent, or less than 3 months, since participation in another non-mesothelioma clinical trial that may affect QOL.
5. Participation in a concurrent mesothelioma trial, within 12 weeks after randomisation, that may affect QOL.
6. Referral at the time of recruitment for cytoreductive, tumour de-bulking, radical decortication or extrapleural pneumonectomy surgery for MPM. (Video Assisted Thoracoscopic Surgery or 'mini' thoracotomy for pleurodesis and diagnosis attempts are permissible.)
7. Chemotherapy treatment for MPM initiated prior to consent.
8. A significant history of depression / anxiety / psychiatric illness requiring specialist hospital care within the last 12 months.

Previous exclusion criteria:

1. Other known malignancy within 5 years (excluding localised squamous cell carcinoma of the skin, cervical intraepithelial neoplasia, grade III and low grade prostate cancer (Gleason score <5, with no metastases)).
2. Significant morbidity which the lead physician (or MDT) feel will unduly confound or influence quality of life (QOL).
3. Those patients the MDT judge require referral to the SPCT at the point of diagnosis.
4. Concurrent, or less than 3 months, since participation in another clinical trial that may affect QOL.
5. Referral at the time of recruitment for cytoreductive, tumour de-bulking, radical decortication or extrapleural pneumonectomy surgery for MPM (Video Assisted Thoracoscopic Surgery or mini thoracotomy for pleurodesis and diagnosis attempts are permissible)
6. Chemotherapy treatment for MPM initiated prior to consent.
7. A significant history of depression / anxiety / psychiatric illness requiring specialist hospital care within the last 12 months.

Date of first enrolment

03/03/2014

Date of final enrolment

30/09/2016

Locations

Countries of recruitment

United Kingdom

England

Wales

Australia

Study participating centre
Queen Alexandra Hospital
United Kingdom
PO6 3LY

Study participating centre
Norfolk & Norwich University Hospital
United Kingdom
NR4 7UY

Study participating centre
University Hospital of North Durham & Darlington Hospital
United Kingdom
DH1 5TW

Study participating centre
North Manchester General Hospital
United Kingdom
M8 5RB

Study participating centre
South Tyneside District Hospital
United Kingdom
NE34 0PL

Study participating centre
New Cross Hospital
United Kingdom
WV10 0QP

Study participating centre

Broomfield Hospital
United Kingdom
CM1 7ET

Study participating centre
Southmead Hospital
United Kingdom
BS10 5NB

Study participating centre
Royal Gwent Hospital
United Kingdom
NP20 2UB

Study participating centre
Great Western Hospital
United Kingdom
SN3 6BB

Study participating centre
Musgrove Park Hospital
United Kingdom
TA1 5DA

Study participating centre
Wythenshawe Hospital
United Kingdom
M23 9LT

Study participating centre
Basildon Hospital
United Kingdom
SS16 5NL

Study participating centre

City Hospital & Sandwell Hospital
United Kingdom
B71 4HJ

Study participating centre
Southampton General Hospital
United Kingdom
SO16 6YD

Study participating centre
Sir Charles Gairdner Hospital
Australia
6009

Study participating centre
Royal Hampshire County Hospital
United Kingdom
SO22 5DG

Study participating centre
North Tyneside General Hospital
United Kingdom
NE29 8NH

Sponsor information

Organisation
Portsmouth Hospitals NHS Trust (UK)

ROR
<https://ror.org/009fk3b63>

Funder(s)

Funder type
Charity

Funder Name

British Lung Foundation (UK) - Asbestos Project Grant Ref.: APG12-13

Alternative Name(s)

BLF

Funding Body Type

Private sector organisation

Funding Body Subtype

Trusts, charities, foundations (both public and private)

Location

United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan**IPD sharing plan summary**

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/04/2019	09/08/2019	Yes	No
Protocol article	protocol	19/09/2014		Yes	No
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes
Plain English results				No	Yes
Study website	Study website	11/11/2025	11/11/2025	No	Yes